Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl- quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1526-1535

  Ismail, Mohamed A H ^a   Barker, Stewart ^b   Abou El Ella, Dalal A ^a   Abouzid, Khaled A M ^a   Toubar, Rabab A ^a   Todd, Matthew H ^c  

^a Ain Shams University   (Egypt)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLSULFANYL 3 [2' (2H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 3H QUINAZOLIN 4 ONE; 3 [2' (2H TETRAZOL 5 YL)BIPHENYL 4 YLMETHYL] 1H QUINAZOLINE 2,4 DIONE; 4' (2 METHYLSULFANYL 4 OXO 4H QUINAZOLIN 3 YLMETHYL)BIPHENYL 2 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; APROVAL; CANDESARTAN HEXETIL; DEOXYCORTICOSTERONE ACETATE; IRBESARTAN; ISOLEUCINE; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; QUINAZOLINE DERIVATIVE; TASOSARTAN; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING ASSAY; CARBON NUCLEAR MAGNETIC RESONANCE; CHO CELL; CONTROLLED STUDY; DISEASE MODEL; DRUG COMPETITION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYPERTENSION; ISOTOPE LABELING; MALE; MOLECULAR MODEL; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; PHARMACOPHORE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; RAT STRAIN; REACTION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIMULATION; THIN LAYER CHROMATOGRAPHY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HYPERTENSION; MALE; MODELS, MOLECULAR; QUINAZOLINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 33644856439     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050232e     Document Type: Article

References (63)

1. (a) Brunner, H. R.; Nussberger, J.; Wäber, B. Angiotensin Antagonists. In The Renin-Angiotensin System; Robertson, J. I. S., Nicholls, M. G., Eds.; Gower Medical Publishing: London, 1993; p 86.1-86.14.
2. (b) Goodfriend, T. L.; Elliott, M. E.; Catt, K. J. Angiotensin Receptors and Their Antagonists. N. Engl. J. Med. 1996, 334, 1649-1654.
3. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J. Hypertens. 2003, 21, 1011-1053.
4. Singh, R. K.; Barker, S. Progress in Development of Angiotensin- Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Curr. Opin. Invest. Drug. 2005, 6, 269-274.
5. Mancia, G.; Seravalle, G.; Grassi, G. Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists. Am. J. Hypertens. 2003, 16, 1066-1073.
6. Furukawa, Y.; Kishimoto, S.; Nishikawa, K. US Patent 4,340,598. 1982.
7. Furukawa, Y.; Kishimoto, S.; Nishikawa, K. US Patent 4,355,040. 1982.
8. Jackson, E. K.; Garrison, J. C. Renin and Angiotensin. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W.; Gilman A. G., Eds.; McGraw-Hill: New York. 1996; pp 733-758.
9. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella J. B.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S.-E.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl) imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
10. (a) Middlemiss, D.; Drew, G. M.; Ross, B. C.; Robertson, M. J.; Scopes, D. I. C.; Dowle, M. D.; Akers, J.; Cardwell, K.; Clark, K. L.; Coote, S.; Eldred, C. D.; Hamblett, J.; Hilditch, A.; Hirst, G. C.; Jack, T.; Montana, J.; Panchal, T. A.; Paton, J. M. S.; Shah, P.; Stuart, G.; Travers, A. Bromobenzofurans: A New Class of Potent Non-Peptide Antagonists of Angiotensin II. Bioorg. Med. Chem. Lett. 1991, 1, 711-716.
11. (b) Palkowitz, A. D.; Steinberg, M. I.; Zimmerman, K. M.; Thrasher, K. J.; Hauser, K. L.; Boyd, D. B. Synthesis and Pharmacological Evaluation of a Novel Series of 5-Aryl Benzimidazole Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 1015-1020.
12. (a) Herr, R. J. 5-Substituted-1H-tetrazoles as Carboxylic Acid Isosteres: Medicinal Chemistry and Synthetic Methods. Bioorg. Med. Chem. 2002, 10, 3379-3393.
13. (b) Bantick, J. R.; Beaton, H. G.; Cooper, S. L.; Hill, S.; Hirst, S. C.; McInally, T.; Spencer, J.; Tinker, A. C.; Willis, P. A. New Non-Peptide Angiotensin II Receptor Antagonists. 2: Structure-Activity Relationships of a Series of Annelated 2(1H)-Pyridinones. Bioorg. Med. Chem. Lett. 1994, 4, 127-132.
14. (c) Bantick, J. R.; Beaton, H. G.; Cooper, S. L.; Hill, S.; Hirst, S. C.; McInally, T.; Spencer, J.; Tinker, A. C.; Willis, P. A. New Non-Peptide Angiotensin II Receptor Antagonists. 1: Structure-Activity Relationships of a Series of Annelated 2(1H)-Pyridinones. Bioorg. Med. Chem. Lett. 1994, 4, 121-126.
15. (d) Zhang, J.; Entzeroth, M.; Wienen, W.; Van Meel, J. C. A. Characterization of BIBS 39 and BIBS 222: Two New Nonpeptide Angiotensin II Receptor Antagonists. Eur. J. Pharmacol. 1992, 218, 35-41.
16. Ries, U. J.; Mihm, G.; Narr, B.; Hasselbach, K. M.; Wittneben, H.; Entzeroth, M.; van Meel, J. C. A.; Wienen, W.; Hauel, N. H. 6-Substituted Benzimidazoles as New Nonpeptide Angiotensin II Receptor Antagonists: Synthesis, Biological Activity, and Structure-Activity Relationships. J. Med. Chem. 1993, 36, 4040-4051.
17. Santella, J. B.; Duncia, J. V.; Ensinger, C. L.; VanAtten, M. K.; Carini, D. J.; Wexler, R. R.; Chiu, A. T.; Wong, P. C.; Timmermans, P. B. M. W. M. Balanced Angiotensin II Receptor Antagonists. III. The Effects of Substitution at the Imidazole 5-Position. Bioorg. Med. Chem. Lett. 1994, 4, 2235-2240.
18. (a) Venkatesan, A. M.; Levin, J. I.; Baker, J. S.; Chan, P. S.; Bailey, T.; Coupet, J. Substituted 4H-Pyrido[1,2-a]pyrimidin-4-one Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 183-188.
19. (b) Levin, J. I.; Venkatesan, A. M.; Chan, P. S.; Baker, J. S.; Francisco, G.; Bailey, T.; Vice, G.; Katocs, A.; Lai, F.; Coupet, J. 2,3,6-Substituted Quinazolinones as Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1135-1140.
20. (c) Levin, J. I.; Chan, P. S.; Coupet, J.; Bailey, T. K.; Vice, G.; Thibault, L.; Lai, F.; Venkatesan, A. M.; Cobuzzi, A. 6-Isoxazolinyl and Isoxazolidinyl Substituted Quinazolinones as Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1703-1708.
21. Levin, J. I.; Chan, P. S.; Coupet, J.; Thibault, L.; Venkatesan, A. M.; Bailey, T. K.; Vice, G.; Cobuzzi, A.; Lai, F.; Mellish, N. Synthesis and Biological Evaluation of the Potent Isoxazolidinyl Angiotensin II Receptor Antagonist CL332,877 and Its Enantiomers. Bioorg. Med. Chem. Lett. 1994, 4, 1709-1714.
22. (e) Levin, J. I.; Venkatesan, A. M.; Chan, P. S.; Bailey, T. K.; Vice, G.; Coupet, J. 6-Substituted Quinazolinone Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1819-1824.
23. 1 Binding Inhibitor. J. Med. Chem. 1993, 36, 3207-3210.
24. (g) Levin, J. I.; Chan, P. S.; Bailey, T.; Katocs, A. S.; Venkatesan, A. M. The Synthesis of 2,3-Dihydro-4(1H)-quinazolinone Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1141-1146.
25. 1-Selective Angiotensin-II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1993, 3, 1293-1298.
26. Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
27. (a) Cottineau, B.; Toto, P.; Marot, C.; Pipaud, A.; Chenault, J. Synthesis and Hypoglycemic Evaluation of Substituted Pyrazole-4-carboxylic Acids. Bioorg. Med. Chem. Lett. 2002, 12, 2105-2108.
28. (b) Mederski, W. W. K. R.; Dorsch, D.; Bokel, H.-H.; Beier, N.; Lues, I.; Schelling, P. Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and Biological Activity of a Series of Novel 4,5-Dihydro-4-oxo-3H-imidazo[4,5-c] pyridine Derivatives. J. Med. Chem. 1994, 37, 1632-1645.
29. (c) Hoover, J. R. E.; Chow, A. W.; Stedman, R. J.; Hall, N. M.; Greenberg, H. S.; Dolan, M. M.; Ferlauto, R. J. Semisynthetic Penicillins. I. 2-Biphenylylpenicillins. J. Med. Chem. 1964, 7, 245-251.
30. Adams, G. L.; Graybill, T. L.; Sanchez, R. M.; Magaard, V. W.; Burton, G.; Rivero, R. A. A Convenient 'Catch and Release' Synthesis of Fused 2-Alkylthio-pyrimidinones Mediated by Polymer-Bound BEMP. Tetrahedron Lett. 2003, 44, 5041-5045.
31. McCarty, J. E.; Haines, E. L.; VanderWerf, C. A. Synthesis of Some Thioquinazolones of Interest as Potential Ataractic Agents. J. Am. Chem. Soc. 1960, 82, 964-966.
32. 1 Angiotensin Receptor. J. Biol. Chem. 1994, 269, 16533-16536.
33. (b) Li, Q.; Pfaffendorf, M.; van Zwieten, P. A. Different Types of Antagonism by Losartan and Irbesartan on the Effects of Angiotensin II and Its Degradation Products in Rabbit Arteries. Fundam. Clin. Pharm. 2001, 15, 143-150.
34. 1 Angiotensin II Receptor Antagonists. J. Med. Chem. 1993, 36, 3371-3380.
35. (b) Quan, M. L.; DeLucca, I.; Boswell, G. A.; Chiu, A. T.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. M. Imidazolinones as Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 1527-1530.
36. (c) Ferrari, B.; Taillades, J.; Perreaut, P.; Bernhart, C.; Gougat, J.; Guiraudou, P.; Cazaubon, C.; Roccon, A.; Nisato, D.; Le Fur, G.; Brelière, J. C. Development of Tetrazole Bioisosteres in Angiotensin II Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 45-50.
37. 2 Enhances the Angiotensin II-Induced DNA Synthesis in Smooth Muscle Cells. Eur. J. Pharmacol. 1996, 307, 121-124.
38. (b) Kubo, K.; Kohara, Y.; Imamiya, E.; Sugiura, Y.; Inada, Y.; Furukawa, Y.; Nishikawa, K.; Naka, T. Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Benzimidazolecarboxylic Acids. J. Med. Chem. 1993, 36, 2182-2195.
39. Brousil, J. A.; Burke, J. M. Olmesartan Medoxomil: An Angiotensin II-Receptor Blocker. Clin. Ther. 2003, 25, 1041-1055.
40. (a) Prendergast, K.; Adams, K.; Greenlee, W. J.; Nachbar, R. B.; Patchett, A. A.; Underwood, D. J. Derivation of a 3D Pharmacophore Model for the Angiotensin-II Site One Receptor. J. Comput. Aid. Mol. Des. 1994, 8, 491-512.
41. (b) Mantlo, N. B.; Chakravarty, P. K.; Ondeyka, D. L.; Siegl, P. K. S.; Chang, R. S.; Lotti, V. J.; Faust, K. A.; Chen, T.-B.; Schorn, T. W.; Sweet, C. S.; Emmert, S. E.; Patchett, A. A.; Greenlee, W. J. Potent, Orally Active Imidazo[4,5-b]pyridine-Based Angiotensin II Receptor Antagonists. J. Med. Chem. 1991, 34, 2919-2922.
42. (c) Krovat, E. M.; Langer, T. Non-Peptide Angiotensin II Receptor Antagonists: Chemical Feature Based Pharmacophore Identification. J. Med. Chem. 2003, 46, 716-726.
43. Kurogi, Y.; Guner, O. F. Pharmacophore Modeling and Three-Dimensional Database Searching for Drug Design Using Catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
44. Smellie, A.; Kahn, S. D.; Teig, S. L. Analysis of Conformational Coverage, 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
45. Barker, S.; Kapas, S.; Fluck, R. J.; Clark, A. J. L. Effects of the Selective Protein Kinase C Inhibitor Ro 31-7549 on Human Angiotensin II Receptor Desensitization and Intracellular Calcium Release. FEBS Lett. 1995, 369, 263-266.
46. 1 Adrenoceptor Subtype Selective Antagonists. Bioorg. Med. Chem. 2000, 8, 201-214.
47. Miyoshi, S.; Ishikawa, H.; Kaneko, T.; Fukui, F.; Tanaka, H.; Maruyama, S. Structures and Activity of Angiotensin-Converting Enzyme Inhibitors in an Alpha-Zein Hydrolysate. Agric. Biol. Chem. 1991, 55, 1313-1318.
48. 1 Receptor Antagonists. Trends Pharmacol. Sci. 2000, 21, 376-381.
49. (b) Lew, M. J.; Christopoulos, A.; Ziogas, J. Non-Surmountable Antagonism: Transcending Steady State-Response from Lew et al. Trends Pharmacol. Sci. 2001, 22, 65-66.
50. 1 Receptor Interaction: Further Support by Binding Studies at Low Temperature. Biochem. Pharmacol. 2003, 65, 1339-1341.
51. 1 Receptor Interaction: An Hypothesis Defended but Not Tested. Biochem. Pharmacol. 2004, 67, 397-399.
52. (a) Vauquelin, G.; Morsing, P.; Fierens, F. L. P.; De Backer, J.-P.; Vanderheyden, P. M. L. A Two-State Receptor Model for the Interaction Between Angiotensin II Type 1 Receptors and Non-Peptide Antagonists. Biochem. Pharmacol. 2001, 61, 277-284.
53. 1-Receptor Agonist and Antagonist Efficacy in Rat Injured Carotid Artery. J. Cardiovas. Pharm. 2000, 35, 693-699.
54. (c) Pantev, E.; Stenman, E.; Wackenfors, A.; Edvinsson, L.; Malmsjo, M. Comparison of the Antagonistic Effects of Different Angiotensin II Receptor Blockers in Human Coronary Arteries. Eur. J. Heart Fail. 2002, 4, 699-705.
55. Takezako, T.; Gogonea, C.; Saad, Y.; Noda, K.; Karnik, S. S. "Network Leaning" as a Mechanism of Insurmountable Antagonism of the Angiotensin II Type 1 Receptor by Non-Peptide Antagonists. J. Biol. Chem. 2004, 279, 15248-15257.
56. Schoen, W. R.; Pisano, J. M.; Prendergast, K.; Wyvratt, M. J.; Fisher, M. H.; Cheng, K.; Chan, W. W.-S.; Butler, B.; Smith, R. G.; Ball, R. G. A Novel 3-Substituted Benzazepinone Growth Hormone Secretagogue (L-692, 429). J. Med. Chem. 1994, 37, 897-906.
57. Carini, D. J.; Duncia, J. J. V. European Patent EP 253310, 1988.
58. Duncia, J. V.; Pierce, M. E.; Santella, J. B. Three Synthetic Routes to a Sterically Hindered Tetrazole. A New One-Step Mild Conversion of an Amide into a Tetrazole. J. Org. Chem. 1991, 56, 2395-2400.
59. (a) Bogert, M. T.; Scatchard, G. Researches on Quinazolines. XXXIII. A New and Sensitive Indicator for Acidimetry and Alkalimetry, and for the Determination of Hydrogen-ion Concentrations between the Limits of 6 and 8 on the Sorensen Scale. J. Am. Chem. Soc. 1916, 38, 1606-1615.
60. (b) Lange, N. A.; Sheibley, F. E. Benzoylene Urea [2,4(1,3)- Quinazolinedione]. Organic Syntheses: Wiley: New York, 1943; Collect. Vol. II, pp 79-81.
61. Gutcait, A.; Wang, K.-C.; Liu, H.-W.; Chern, J.-W. Studies on Quinazolines. 6. Asymmetric Synthesis of (S)-(+)- and (R)-(-)-3-[[4-(2- Methoxyphenyl)piperazin-1-yl]methyl]-5-methylthio-2,3-dihydroimidazo[1,2-c] quinazolines. Tetrahedron: Asymmetry 1996, 7, 1641-1648.
62. Liljefors, T.; Pettersson, I. Computer-aided Development and Use of Three-Dimensional Pharmacophore Models. In Textbook of Drug Design and Discovery, 3rd ed.; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Taylor and Francis Inc.: New York, 2002; pp 86-116.
63. 1B Angiotensin II Receptors and Angiotensin II Receptor Isoforms in Rat Tissues Using Isoelectric Focusing. Biochem. Biophys. Res. Commun. 1993, 192, 392-398.